Tenofovir and fibrosis improvement in chronic hepatitis B: insights from a case series

Tenofovir is a primary treatment for chronic hepatitis B (CHB) infections. While hepatic fibrosis regression during antiviral therapy has been documented, data on the effects of prolonged tenofovir disoproxil fumarate (TDF) treatment on Fibroscan results is limited. This case series will significantly contribute to the understanding of fibrosis improvement in CHB patients undergoing long-term TDF therapy. We present four patients with CHB patients receiving long-term TDF therapy. Fibrosis levels were assessed using Fibroscan before and after treatment to evaluate changes in hepatic fibrosis. Overall, these cases underscore that timely initiation of antiviral therapy, coupled with regular monitoring, can lead to significant improvements in liver function and fibrosis in CHB patients. The findings support the notion that effective antiviral treatments can reverse the course of liver disease, reduce complication risks, and enhance overall patient well-being. • The manuscript discusses case studies showing that Tenofovir effectively improves liver fibrosis and viral suppression in chronic hepatitis B patients. • It emphasizes the importance of early diagnosis, continuous monitoring, and treatment adherence for positive outcomes. • The study advocates for a comprehensive management approach, including antiviral therapy, lifestyle modifications, and individualized care, supported by real-world evidence.